---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-016839"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2024-04-29T23:59:59+00:00"
generated_at: "2026-06-03T06:06:37.704050+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Oncotelic sells necroptosis cancer therapy assets to Mosaic for up to $30M

## Summary
- Mosaic to issue $15M in shares at closing; Oncotelic may earn $15M more in cash/shares based on milestones.
- Transaction includes Oncotelic's CA4P clinical-stage necroptosis therapies and AI tech for immunotherapy combos.
- Mosaic to fund $2.0-$2.5M annual development budget; Oncotelic to loan short-term operational costs until June 1, 2024.
- If Oncotelic cannot help raise $2M for Mosaic, transaction may become reverse merger.
- Parties to negotiate definitive agreement; closing subject to customary due diligence.

## SEC filing metadata
- accession: 0001493152-24-016839
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2024-04-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315224016839/0001493152-24-016839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315224016839/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-016839
- JSON: https://secwatch.observer/filing/0001493152-24-016839.json
- Plain text: https://secwatch.observer/filing/0001493152-24-016839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.